Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Caredx Inc (CDNA)

Caredx Inc (CDNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
3d illustration inflation and deflation graph by Deepadesigns via Shutterstock
CareDx Stock Is Up 300% Over the Past Year. Here’s How Much Upside Is Left. Barchart - Mon Aug 10, 3:20PM CDT

CareDx (CDNA) has surged 300% over the past year, driven by robust technical momentum and strong buy signals. CDNA is rated a “Strong Buy” by several analysts, with consensus price targets suggesting...

CDNA : 47.38 (+0.15%)
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire - Fri Aug 7, 3:01PM CDT

CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the award of inducement grants. On August...

CDNA : 47.38 (+0.15%)
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire - Fri Jul 31, 5:45PM CDT

CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced that, on July 30, 2026, CareDx granted to James McNally,...

CDNA : 47.38 (+0.15%)
CareDx: Q2 Earnings Snapshot AP - Thu Jul 30, 3:22PM CDT

CareDx: Q2 Earnings Snapshot

CDNA : 47.38 (+0.15%)
CareDx Announces Second Quarter 2026 Financial Results Business Wire - Thu Jul 30, 3:01PM CDT

Second Quarter Revenue Growth of 52% to $132 Million Raises 2026 Revenue Guidance to $490 Million to $500 Million and Raises 2026 AEBITDA Guidance to $66 Million to $78...

CDNA : 47.38 (+0.15%)
CareDx's First Report Under Final Medicare Rules Will Reveal How Test Limits Actually Work Barchart - Wed Jul 29, 4:06PM CDT

Barchart Research What to Expect from CDNA Earnings CDNA Generated July 29, 2026 Current Price $35.41 EPS Estimate $$0.06 Consensus Rating Moderate Buy Average Move 7.48% CareDx's First Report Under Final...

CDNA : 47.38 (+0.15%)
CareDx to Report Second Quarter 2026 Financial Results on July 30, 2026 Business Wire - Thu Jul 16, 7:35AM CDT

CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced it will report financial results for the second quarter...

CDNA : 47.38 (+0.15%)
CareDx Announces Finalization of Solid Organ Transplant Molecular Testing Local Coverage Determination Business Wire - Thu Jul 16, 7:30AM CDT

Coverage for Surveillance Testing Affirmed for Early Detection of Allograft Rejection in Kidney, Heart, and Lung

CDNA : 47.38 (+0.15%)
CareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty Oncology Business Wire - Wed Jul 1, 3:05PM CDT

NavDx ® is the only Medicare-covered MRD test for HPV-positive Head & Neck and Anal Cancers Expands CareDx’s estimated addressable market...

CDNA : 47.38 (+0.15%)
CareDx Announces Completion of Sale of Lab Products Business to Eurobio Scientific Business Wire - Tue Jun 30, 3:05PM CDT

Sharpens focus on U.S. precision medicine Testing Services and Patient & Digital Solutions

CDNA : 47.38 (+0.15%)

Barchart Exclusives

H&R Block Posted Strong Earnings and Boosted Its Dividend by Nearly 10%. What This Means for HRB Stock. Barchart - 1 hour ago
H&R Block beat fiscal fourth-quarter estimates, raised its fiscal 2027 outlook, and increased its quarterly dividend by nearly 10% to $0.46 per share, sending the stock up about 16%. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.